FDA Designated Canine Bone Cancer Drug Minor Use
Veterinary treatment CannEpil may reach the U.S. market by 2027 to manage bone cancer pain in dogs.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Should the FDA accelerate approval processes for drugs treating uncommon health conditions in pets?
The FDA Center for Veterinary Medicine has granted minor-use drug status to CannEpil, an investigational oral solution intended to treat bone cancer pain in dogs. This designation allows the developers to pursue a conditional approval pathway to help bring the treatment to market.
Why it matters
The MUMS program was established to incentivize the development of medications for uncommon conditions that affect smaller animal populations. This status streamlines the regulatory process, potentially increasing access to pain management options for dogs with rare or specialized veterinary needs.
The FDA classified CannEpil as a minor-use drug under the MUMS program, a designation granted to treatments for uncommon conditions. While this path allows for conditional approval, the developer must still meet rigorous manufacturing and safety standards.
The players
FDA Center for Veterinary Medicine
The federal agency responsible for regulating animal drugs and ensuring the safety of the veterinary medical supply.
Endovia
A pharmaceutical developer focusing on cannabinoid-based solutions for veterinary pain management.
Lupvindol
A life sciences company partnering on the manufacturing and development of the CannEpil oral solution.
The details
CannEpil is an investigational oral solution containing both CBD and THC intended to manage pain. Under the FDA conditional approval pathway, companies must satisfy safety and manufacturing requirements before they are permitted to collect the additional effectiveness data necessary for a full drug approval application. Developers Endovia and Lupvindol are currently establishing a U.S.-based manufacturing supply chain to support these regulatory efforts.
Timeline
October 5, 2026: The FDA announced the minor-use determination for CannEpil.
November 19, 2026: Endovia and Lupvindol are scheduled to meet with the FDA.
2027: The developers anticipate a potential commercial veterinary launch.
Health Landscape
This designation follows the regulatory framework established by the MUMS program to support treatments for rare animal conditions. It represents a shift toward expanding specialized pain management tools in the veterinary oncology market.
Pet owners currently managing canine bone cancer pain should discuss new treatment options and potential clinical trial availability with their veterinarian. This designation indicates a developing regulatory path that may offer new alternatives for pain management in the coming years.
The takeaway
The FDA has taken a step toward approving a new CBD and THC-based pain treatment for dogs by designating it a minor-use drug. Owners of pets with cancer should continue to monitor updates through their primary veterinarian as the drug moves through the regulatory process.
What happens next
Endovia and Lupvindol are scheduled to participate in a pre-submission conference with the FDA on November 19, 2026.
Further reading
Learn more about the latest developments in veterinary oncology treatments by visiting Cancer.
Live Poll
Should the FDA accelerate approval processes for drugs treating uncommon health conditions in pets?
